Skip to content
10-Q

Quarterly Report

PATHFINDER CELL THERAPY, INC.

0001213900-15-008536

← back to feed
Filed
Nov 13, 2015 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2015 · Sep 30, 2015 667.16M sh
Operating Cash Flow Q3 2015 · Sep 30, 2015 −$452K
Operating Cash Flow Q3 2015 · Sep 30, 2014 −$836K
Cash And Equivalents Q3 2015 · Sep 30, 2015 $4K
Cash And Equivalents Q3 2015 · Dec 31, 2014 $26K
Cash And Equivalents Q3 2015 · Sep 30, 2014 $23K
Cash And Equivalents Q3 2015 · Dec 31, 2013 $44K
Stockholders Equity Q3 2015 · Sep 30, 2015 −$6.73M
Stockholders Equity Q3 2015 · Dec 31, 2014 −$5.94M
Current Liabilities Q3 2015 · Sep 30, 2015 $6.77M
Current Liabilities Q3 2015 · Dec 31, 2014 $6.05M
Current Assets Q3 2015 · Sep 30, 2015 $9K
Current Assets Q3 2015 · Dec 31, 2014 $73K
Total Assets Q3 2015 · Sep 30, 2015 $39K
Total Assets Q3 2015 · Dec 31, 2014 $106K
Sga Expense Q3 2015 · Sep 30, 2015 $138K
Sga Expense Q3 2015 · Sep 30, 2015 $446K
Sga Expense Q3 2015 · Sep 30, 2014 $187K
Sga Expense Q3 2015 · Sep 30, 2014 $687K
Rd Expense Q3 2015 · Sep 30, 2015 $71K
Rd Expense Q3 2015 · Sep 30, 2015 $111K
Rd Expense Q3 2015 · Sep 30, 2014 $26K
Rd Expense Q3 2015 · Sep 30, 2014 $209K
Net Income Q3 2015 · Sep 30, 2015 −$289K
Net Income Q3 2015 · Sep 30, 2015 −$787K
Net Income Q3 2015 · Sep 30, 2014 −$284K
Net Income Q3 2015 · Sep 30, 2014 −$1.1M
Operating Income Q3 2015 · Sep 30, 2015 −$209K
Operating Income Q3 2015 · Sep 30, 2015 −$557K
Operating Income Q3 2015 · Sep 30, 2014 −$213K
Operating Income Q3 2015 · Sep 30, 2014 −$901K